| John Koconis |
Currently, John Koconis is Chairman, President & Chief Executive Officer for Timber Pharmaceuticals, Inc.
In the past Mr. Koconis occupied the position of Principal at Abbott Laboratories, Chief Commercial Officer & Executive VP for Castle Creek Biosciences, Inc., President & Chief Executive Officer at Leo Pharma, Inc., Chief Executive Officer of Timber Pharmaceuticals LLC, Head-Global Dermatology & Respiratory at Genzyme Corp., Principal at LEO Pharma An and Head-Global Dermatology & Respiratory at Genzyme Therapeutics Ltd.
Mr. Koconis received an undergraduate degree from Loyola University of Chicago and an MBA from Quinlan School of Business. |
| Jessica Bruno-Raiz |
Jessica Bruno-Raiz holds the position of VP-Clinical Operations & Program Management at Timber Pharmaceuticals, Inc.
In her past career she was Director-Clinical Operations at Champions Oncology, Inc. and Director-Clinical Operations at Ferring Pharmaceuticals, Inc.
She received an undergraduate degree from Drew University and a graduate degree from Boston University School of Medicine. |
| Joseph Lucchese |
Presently, Joseph Lucchese occupies the position of CFO, Secretary, Treasurer & Executive VP at Timber Pharmaceuticals, Inc. and Chief Financial Officer for Timber Pharmaceuticals LLC (a subsidiary of Timber Pharmaceuticals, Inc.). He is also on the board of Garuda Bio LLC.
In his past career Joseph Lucchese held the position of President & Chief Financial Officer for Chess Therapeutics LLC, Chief Financial Officer for PaxMedica, Inc., Managing Director at Bluestone Capital Partners LP, Managing Partner at Foundation Ventures LLC, Partner at TardiMed Sciences LLC, Managing Director & Founding Member at Oncology Partners LLC, Chief Financial Officer for The MicroCap Fund, Inc., Member-Merchant Banking Group at Chase Bank USA, NA and Managing Director at ASR Group Europe Ltd.
Joseph Lucchese received an undergraduate degree from Fordham University. |
| Alan Mendelsohn |
Currently, Alan Mendelsohn holds the position of Chief Medical Officer & Executive Vice President at Timber Pharmaceuticals, Inc.
In his past career Dr. Mendelsohn was Senior Director-Immunology Research & Development at Johnson & Johnson and Associate VP-Dermatology Medical Affairs at Sun Pharmaceutical Industries Ltd.
Alan Mendelsohn received a doctorate from State University of New York at Downstate Medical Center. |
| Gianluca Pirozzi |
Currently, Gianluca Pirozzi holds the position of Senior VP, Head-Development, Regulatory & Safety at Alexion Pharmaceuticals, Inc. He is also on the board of Timber Pharmaceuticals, Inc.
In his past career he was Head-Gene Therapy at Genzyme Therapeutics Ltd., Head-Development for Rare Diseases & Gene Therapy at Sanofi SA and Head-Rare Diseases at Genzyme Corp.
He received a doctorate from Sapienza University of Rome and a doctorate from Università Campus Bio-Medico di Roma. |
| Lubor Gaal |
Presently, Lubor Gaal holds the position of Chief Financial Officer at Circio Holding ASA. He is also on the board of Timber Pharmaceuticals, Inc.
He previously was Head-Neuroscience, Immunoscience & Fibrosis at Bristol Myers Squibb Co., Head-CNS & CV Licensing at Bayer AG, Senior Vice President & Head-Europe at Locust Walk Partners LLC, Head-External Innovation & Licensing at Almirall SA and Head-Sales & Marketing at Neuro3D SA.
Dr. Gaal received an undergraduate degree from the University of Sussex and a doctorate from the University of California. |
| David Eric Cohen |
David Eric Cohen is on the board of Kadmon Holdings, Inc., American Dermatological Association, Inc. (former President), Timber Pharmaceuticals, Inc. and Evommune, Inc. and Professor at New York University and Dermatology Professor at New York University School of Medicine.
In his past career Dr. Cohen occupied the position of President at American Contact Dermatitis Society, Member of American Academy of Dermatology, Chief Resident-Dermatology Department at NYU Elaine A. & Kenneth G. Langone Medical Center and President-Dermatology Section at The New York Academy of Medicine.
David Eric Cohen received an undergraduate degree from City University of New York, a doctorate from Stony Brook University School of Medicine, a graduate degree from Joseph L. Mailman School of Public Health and a graduate degree from The Trustees of Columbia University in The City of New York. |
| Edward J. Sitar |
Edward J. Sitar occupies the position of Chief Financial Officer for Variantyx, Inc. He is also on the board of Timber Pharmaceuticals, Inc.
In the past Mr. Sitar was Chief Financial Officer for SchoolCare, Inc., Chief Financial Officer at Ammon Analytical Laboratories, Inc., Chief Financial & Accounting Officer at 9 Meters Biopharma, Inc., Vice President-Finance for Vital Signs, Inc., Chief Financial Officer & Treasurer at MIM Corp., Chief Financial Officer & Executive Vice President at Cadent Holdings, Inc., Chief Financial Officer, Secretary & Treasurer of Cancer Genetics, Inc., Chief Financial Officer of BioScrip, Inc., Chief Financial Officer at Active Health Management, Inc. (New York), Chief Financial Officer & Executive Vice President at Cadent, Inc., Senior Manager at Coopers & Lybrand LLP, Chief Financial Officer-New Business at M1 Holdings LLC (Colorado) and Controller of IVAX Pharmaceuticals, Inc.
Edward J. Sitar received an undergraduate degree from the University of Scranton. |
